CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: A randomised trial (GABG trial IV-A-93)

European Journal of Cancer

Volumn 42, Issue 12, 2006, Pages 1780-1788

  von Minckwitz, Gunter ^a,k   Graf, Erika ^b   Geberth, Matthias ^c   Eiermann, Wolfgang ^d   Jonat, Walter ^e   Conrad, Bettina ^f   Brunnert, Klaus ^g   Gerber, Bernd ^h   Vescia, Sabine ⁱ   Wollert, Jörg ^j   Kaufmann, Manfred ^k  

^a GERMAN BREAST GROUP   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d Rot Kreuz Krankenhaus   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f Senologisches Zentrum   (Germany)

^g Klinik Fur Senologie   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ City Hospital Hanau   (Germany)

^j ASTRAZENECA   (United Kingdom)

^k UNIVERSITY HOSPITAL FRANKFURT   (Germany)

more..

Author keywords

Breast cancer; Chemotherapy; CMF; GnRH; Goserelin; Node negative; Ovarian ablation; Premenopausal

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; METHOTREXATE; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LYMPH NODE METASTASIS; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33746762916     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.04.006     Document Type: Article

References (26)

1. Beatson G.T. On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 2 (1898) 104-162
2. Early Breast Cancer Trialist's Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
3. Dees E.C., and Davidson N.E. Ovarian ablation as adjuvant therapy for breast cancer. Semin Oncol 28 (2001) 322-331
4. Goldhirsch A., Wood W.C., Gelber R.D., et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21 (2003) 3357-3365
5. Maass H.H. 3 versus 6 cycles of CMF in breast cancer patients with 1 to 9 positive nodes: results of the German Adjuvant Breast Cancer Group (GABG) III Trial. Proc ASCO 19 (2000) 283
6. Schumacher M., Bastert G., Bojar H., et al. Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group. J Clin Oncol 12 (1994) 2086-2093
7. International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996;14:1885-1894.
8. Colleoni M., Litman H.J., Castiglione-Gertsch M., et al. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer 86 (2002) 1705-1714
9. Jonat W., Kaufmann M., Sauerbrei W., et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20 (2002) 4628-4635
10. Kaufmann M., Jonat W., Blamey R., et al. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39 (2003) 1711-1717
11. von Minckwitz G., von der Assen A., Blohmer J.U., et al. Medical ovarian ablation (Goserelin 2 yrs.) versus polychemotherapy (CMF x 3) in premenopausal patients with node-negative, receptor positive breast cancer - GABG trial 'IV-A-93'. The Breast 10 suppl 1 (2001) S28 abstr
12. von Minckwitz G., Graf E., Geberth M., et al. Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 Trial. Proc ASCO 23 (2004) 534 abstr
13. Remmele W., and Stegner H.E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8 (1987) 138-140
14. Schmoor C., Olschewski M., Sauerbrei W., et al. Long-term follow-up of patients in four prospective studies of the German Breast Cancer Study Group (GBSG): a summary of key results. Onkologie 25 (2002) 143-150
15. Schoenfeld D.A. Sample-size formula for the proportional-hazards regression model. Biometrics 39 (1983) 499-503
16. Schemper M., and Smith T.L. A note on quantifying follow-up in studies of failure time. Cont Clin Trials 17 (1996) 343-346
17. Clark T.G., Altman D.G., and De Stavola B.L. Quantification of the completeness of follow-up. Lancet 359 (2002) 1309-1310
18. Kalbfleisch J.D., and Prentice R.L. The statistical analysis of failure time data (1980), Wiley, New York
19. Rutgers E.J. EUSOMA Consensus Group. Quality control in the locoregional treatment of breast cancer. Eur J Cancer 37 (2001) 447-453
20. Kaufmann M., Graf E., Jonat W., et al. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93). J Clin Oncol 23 (2005) 7842-7848
21. Kaufmann M., Graf E., Jonat W., et al. Goserelin versus control after adjuvant, riskadapted chemotherapy in premenopausal patients with breast cancer: GABG-IV B-93. J Clin Oncol 22 14S (2004) 588 abstr
22. Eiermann W., Graf E., Raab G., et al. Highdose epirubicin vs. standard-dose epirubicin cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: First results of a randomised trial of the German Adjuvant Breast Cancer Group (GABG). Proc Am Soc Clin Oncol 20 (2001) A-127 abstr 127
23. Kaufmann M., Jonat W., Blamey R., et al. Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39 (2003) 1711-1717
24. Castiglione-Gertsch M., O'Neill A., Price K.N., et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomised trial. J Natl Cancer Inst 95 (2003) 1833-1846
25. Engelsman E., Klijn J.C., Rubens R.D., et al. 'Classical' CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer 27 (1991) 966-970
26. Jakesz R., Hausmanninger, Kubista E., et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20 (2002) 4621-4627